Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $90,200.00 in Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CFO Avraham Gabay sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the completion of the sale, the chief financial officer owned 861,076 shares of the company’s stock, valued at approximately $3,883,452.76. The trade was a 2.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oramed Pharmaceuticals Stock Up 0.2%

Shares of Oramed Pharmaceuticals stock traded up $0.01 during trading on Friday, reaching $4.49. The company’s stock had a trading volume of 178,322 shares, compared to its average volume of 227,288. Oramed Pharmaceuticals Inc. has a 52-week low of $2.09 and a 52-week high of $5.47. The company has a market cap of $186.78 million, a price-to-earnings ratio of 1.09 and a beta of 1.29. The firm’s 50-day moving average is $4.64 and its two-hundred day moving average is $4.19.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). On average, equities research analysts anticipate that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current year.

Institutional Trading of Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SB Capital Management Inc bought a new stake in Oramed Pharmaceuticals in the fourth quarter valued at $5,415,000. Dimensional Fund Advisors LP lifted its position in shares of Oramed Pharmaceuticals by 5.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 7,738 shares during the period. Ritholtz Wealth Management bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at about $529,000. Bank of America Corp DE boosted its stake in shares of Oramed Pharmaceuticals by 2.7% during the 1st quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock valued at $497,000 after purchasing an additional 3,909 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Oramed Pharmaceuticals during the second quarter valued at about $381,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ORMP. Wall Street Zen upgraded Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Oramed Pharmaceuticals in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing orally administered therapies that are traditionally delivered by injection. The company’s technology is designed to protect therapeutic proteins and peptides as they pass through the digestive system and facilitate their absorption in the body.

Oramed’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) analog candidate.